Wed. 28 Feb 2024, 4:35pm ET
Benzinga
Earnings, News
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.86) by 4.65 percent. This is a 7.14 percent decrease over losses of $(0.84) per share from the same period last year.